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SUMMARY
 
Many studies on the role of merozoite surface protein 3
(MSP3) in immunity against malaria have focused on a
conserved section of MSP3. New evidence suggests that poly-
morphic sequences within MSP3 are under immune selection.
We report a detailed analysis of naturally-acquired antibodies
to allele-specific and conserved parts of MSP3 in a Kenyan
cohort. Indirect and competition ELISA to heterologous
recombinant MSP3 proteins were used for antibody assays, and
parasites were genotyped for msp3 alleles. Antibody reactivity
to allele-specific and conserved epitopes of MSP3 was heter-
ogenous between individuals. Overall, the prevalence of allele-
specific antibody reactivity was significantly higher (3D7-specific
54%, K1-specific 41%) than that to a recombinant protein
representing a conserved portion of C-terminal MSP3 (24%,
 
P < 
 
0·01). The most abundant IgG subclass was IgG3, followed
by IgG1. Allele-specific reactivity to the K1-type of MSP3
was associated with a lower risk of clinical malaria episodes
during a 6-month follow-up in individuals who were parasitized
at the start of the malaria transmission season (Relative risk
0·41 with 95% confidence interval 0·20–0·81,
 
 P = 
 
0·011). The
potential importance of allele-specific immunity to MSP3
should be considered in addition to immunity to conserved
epitopes, in the development of an MSP3 malaria vaccine.
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INTRODUCTION
 
Recent estimates of the global burden of malaria indicate
that about 515 million clinical attacks were attributable to
 
Plasmodium falciparum 
 
in 2002, with the majority (70%) of
these episodes occurring in Africa (1) where young children
account for 90% of all malaria deaths (2). An effective, safe
and affordable malaria vaccine would be of  enormous
benefit for resource-poor countries, but remains elusive (3).
Understanding the naturally acquired immunity (NAI) to
malaria that is evident in older children and adults living
in endemic areas is important for the selection of realistic
vaccine targets and provides a reference against which the
effectiveness of new vaccines can be compared. Although
the mechanisms underlying NAI are incompletely under-
stood, there is strong evidence to suggest that antibodies are
centrally important (4,5). Red cell invasion is a critical point
in the life cycle of parasite at which merozoites are briefly
exposed to the host immune system and can therefore be
targeted by antibodies. Naturally occurring antibodies to
many merozoite recombinant antigens have been demon-
strated in malaria endemic populations. Some of  these
antigens are currently under development as components of
experimental vaccines.
Merozoite surface protein 3 (MSP3) is a polymorphic
parasite antigen that may have a role in parasite invasion, as
truncation of the 
 
MSP3 
 
gene reduces parasite invasion of
erythrocytes (6). Structurally, MSP3 is composed of three
blocks of  four heptad repeats with the motif  AXXAXXX,
a hydrophilic region and a putative leucine zipper sequence
at the C-terminus (7). Variation between alleles of  
 
MSP3
 
in 
 
P. falciparum 
 
is due to substitutions and deletions in non-
repetitive sequences within and flanking the region encoding
the alanine-heptad repeat domains. Comparison of sequences
of 
 
P. falciparum 
 
from isolates collected from diverse geo-
graphical locations reveals a distinct dimorphism, with allelic
sequences falling into major types, 
 
3D7-like
 
 and 
 
K1-like
 
 (8).
MSP3 is currently under development as a malaria vac-
cine candidate, and evidence that it is a target of NAI is
 
Correspondence
 
: F. H. A. Osier, KEMRI/Centre for Geographic 
Medicine Research-Coast, PO Box 230, Kilifi-80108, Kenya 
(e-mail: fosier@kilifi.kemri-wellcome.org).
 
Received: 24 January 2007
Accepted for publication: 15 March 2007
 
Re-use of this article is permitted in accordance with the 
Creative Commons Deed, Attribution 2·5, which does not permit 
commercial exploitation.
 388
 
© 2007 The Authors
Journal compilation © 2007 Blackwell Publishing Ltd, 
 
Parasite Immunology
 
, 
 
29
 
, 387–394
 
F. H. A. Osier 
 
et al.
 
Parasite Immunology
 
accumulating. A vaccine incorporating a portion of  the
conserved C-terminal of MSP3 was safe, immunogenic and
induced antibodies with a strong anti-parasite effect (9),
which was still evident 12 months post-vaccination (10).
Antibodies to this conserved portion of  MSP3 mediate
antibody dependent cellular inhibition (ADCI) of parasite
growth in conjunction with monocytes 
 
in vitro
 
 (11), and
in an immunodeficient 
 
in vivo
 
 mouse model (12,13). In
vaccination experiments with MSP3, 
 
Saimiri sciureus
 
 (14)
and 
 
Aotus nancymai
 
 (15) monkeys have been protected from
lethal challenge with malaria. More recently, in longitudinal
studies in endemic populations, antibodies to both conserved
(13,16,17) and allele-specific (18) epitopes of MSP3 have
been associated with reduced risk of malaria. Finally, pop-
ulation genetic analyses indicate that MSP3 may be under
selection that maintains the polymorphisms (18).
We investigated the prevalence of allele-specific and con-
served antibodies to 
 
Escherichia coli 
 
expressed recombinant
MSP3 proteins, and determined whether these antibodies
were associated with protection in a longitudinal study in
a rural community in Kenya. We also examined the subclass
pattern of IgG antibodies to MSP3 and the allele frequencies
of 
 
msp3
 
 in the local parasite population.
 
MATERIALS AND METHODS
 
Study population
 
The study was conducted in Chonyi, a rural village in Kilifi
district on the Kenyan Coast, which typically experiences
two seasonal peaks in malaria transmission (June to August,
November to December). The average annual entomological
inoculation rate (EIR) is between 20 and 100 infective bites/
person/year (19). Informed consent was obtained from all
study participants and epidemiological details of  this lon-
gitudinal cohort are published (20). Briefly, in October 2000,
a cross-sectional survey was conducted in which venous
blood samples were obtained for thick and thin peripheral
blood smears to detect malaria parasites, and the separated
serum was stored for assays of anti-malarial antibodies. In
the ensuing 26 weeks, study participants were followed up
for clinical episodes of malaria by both active and passive
case detection. Episodes of malaria were monitored by
weekly visits to the participant’s homes, where temperatures
were recorded and the presence of parasitaemia detected by
microscopy of Giemsa-stained thick and thin peripheral
blood smears, on a single slide that was prepared for those
found to be febrile. One hundred high power fields were
examined before a slide was reported as negative. Participants
found to be unwell were treated and had open access to an
outpatient clinic at the local district hospital. Malaria was
defined as a fever of greater than 37·5
 
°
 
C with a parasitaemia
of greater than 2500/
 
µ
 
L of blood in subjects over a year old.
For infants (< 1 year-old) a fever (axillary temperature over
37·5
 
°
 
C) plus any parasitaemia was counted as a clinical
episode of  malaria. These have been determined to be the
optimal definitions for malaria in the different age-groups
in this community (20). Data on 536 individuals were available
for a minimum of 23 of the 26 weekly surveys, as previously
described (21,22) and sera from these individuals are analysed
here. Ethical approval was granted by the Kenya National
Research Ethics Committee.
 
Recombinant antigens and antibody assays
 
Full length recombinant antigens representing both of the
dimorphic types of  MSP3 (3D7 and K1), were used as
previously described (18). Both antigens were expressed in
 
E. coli 
 
as fusion products bound to maltose binding protein
(MBP). At the amino acid level the two antigens differ
both as a consequence of replacement polymorphisms (46
positions), as well as deletions, found in one sequence but
not in the other (35 and 2 amino acid deletions in 3D7 and
K1, with respect to each other), with the majority of  the
differences occurring in the N-terminal half  of the sequence.
A third antigen, representing a portion of  the relatively
conserved C-terminal of  MSP3 (codons 234–354 of  the
3D7 allele) was also expressed (18).
 
Indirect ELISA
 
To measure specific IgG, indirect ELISA assays were
performed in duplicate for each serum sample against each
of the MSP3 proteins (3D7, K1 and C-terminal), and the
fusion partner alone (MBP) using methods previously
described (18). Briefly, individual wells of Dynex Immunolon
4HBX ELISA plates (Dynex Technologies Inc, Chantilli, VA,
USA) were coated with 50 ng of  antigen per 100 
 
µ
 
L of
carbonate coating buffer (15 m
 

 
 Na
 
2
 
CO
 
3
 
, 35 m
 

 
 NAHCO3,
pH 9·3). 
 
Plasmodium falciparum
 
 (A4 strain) schizont extract
was coated onto wells in PBS. Plates were incubated over-
night at 4
 
°
 
C, after which wells were washed four times in
PBS/Tween (Phosphate Buffered Saline/0·05% Tween 20),
and blocked for 5 h at room temperature with 1% skimmed
milk in PBS/Tween (blocking buffer). Wells were washed
again and incubated overnight at 4
 
°
 
C with 100 
 
µ
 
L of test
sera (1/1000 dilution in blocking buffer). Plates were then
washed four times and incubated for 3 h at room tempera-
ture with 100 
 
µ
 
L of HRP-conjugated rabbit anti-human IgG
(Dako Ltd, Buckinghamshire, UK) at 1/5000 dilution in
blocking buffer before final washing and detection with
H
 
2
 
O
 
2
 
 and 
 
O
 
-phenylenediamine (Sigma, St. Louis, MO, USA).
The reaction was stopped with 25 
 
µ
 
L of 2 
 

 
 H
 
2
 
SO
 
4
 
 per well
and absorbance read at 492 nm. The optical density (OD) for
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antibodies to MBP alone was subtracted from that of anti-
bodies to the K1, 3D7 and C-terminal MSP3. The cut-off OD
for positivity was determined by taking the mean + 3 SD of
20 negative control sera from UK residents and was 0·26 for
3D7 MSP3, 0·32 for K1 MSP3 and 0·20 for C-terminal MSP3.
Competition ELISA assays were performed on samples
that were positive for both the 3D7 and K1 MSP3 proteins
(
 
n
 
 = 258) to test for the presence of  antibodies that dis-
tinguish each of the allelic types. For this assay, test sera were
preincubated for 5 h with an excess of competing antigen
(1000 ng) before following the indirect ELISA protocol for
bound antigen. Any epitopes that are shared between the
competing and plate bound antigens alleles would thus be
blocked in the preincubation step. To confirm the presence
of allele-specific reactivity, selected sera (
 
n
 
 = 20) were further
explored using competition ELISA with titred amounts of
competing antigen (ranging from 0 to 1000 ng). Four sets of
sera, each containing five samples, were selected as follows
(1): sera with strong reactivity (OD > 2·0) to K1 MSP3 and
very low or no reactivity to 3D7 MSP3 (2); sera with
moderate/strong reactivity (OD > 1·5) to 3D7 MSP3 and
very low or no reactivity to K1 MSP3 (3); sera that had
strong reactivity (OD > 2·0) to both allelic antigens (4); sera
that had moderate reactivity (OD 1·5–2·0) to both allelic
antigens. Competing antigens were either homologous to
plate coated antigen (e.g. K1 MSP3 coated on plate and
K1 MSP3 preincubated with test sera) or heterologous (e.g.
K1 MSP3 coated on plate and 3D7 MSP3 preincubated
with test sera). For each sample, a difference in OD of > 0·3
between the heterologous and homologous assays was
counted as evidence of allele-specific reactivity as this cut-
off  was considered to represent a substantial reactivity and
gave consistent assessments of allele-specific reactivity when
the assays were repeated on three separate days.
To determine which IgG subclasses against MSP3 were
predominant, a subset of 96 sera that was positive for both
MSP3 antigens were tested. The assays were identical to that
of  total IgG except HRP-conjugated polyclonal sheep
antibodies specific for human IgG1, IgG2, IgG3 and IgG4
(The Binding Site, Birmingham, UK) at 1/3000 dilution
were used as secondary antibodies. To estimate the amount
of each of the IgG subclass antibodies bound to the antigens,
standard curves were generated using titred amounts
(doubling dilutions from 10 to 0·005 
 
µ
 
g/mL) of  purified
human myeloma proteins coated on ELISA plates and used
for interpolation of antibody amounts in test sera.
 
Parasite 
 
msp3
 
 genotyping
 
Parasite DNA was available from blood samples collected
at the cross-sectional time point in October 2000 from 85
individuals who were parasite positive, and was extracted
from 100 
 
µ
 
L of packed blood cells using the Qiamp DNA
mini kit (Qiagen, UK). Allelic typing of the major dimorphism
in 
 
msp3
 
 was performed by semi-nested PCR on genomic
DNA followed by sequence-specific oligonucleotide probing
(SSOP). The outer PCR primers were 
 
370F
 
 5
 
′
 
-TGTACAG-
CTGCTTCAAAGG-3
 
′
 
 and 
 
586R
 
 5
 
′
 
-CTCCTCCAAATTC-
CCAACC-3
 
′
 
, followed by a second round reaction using the
same forward primer and 
 
520R
 
 5
 
′
 
-TTGGTTTGCTTTTT-
GATAAGC-3
 
′
 
 as the reverse primer (primers designed to
conserved sequences in 
 
msp3
 
). PCR reactions were performed
in 20 
 
µ
 
L volumes in 96 well plates using 100 n
 

 
 primers with
initial template denaturation at 94
 
°
 
C for 2 min, followed by
44 cycles of 94
 
°
 
C for 1 min, 50
 
°
 
C for 1 min,and 72
 
°
 
C for
1·5 min, with a final extension of 72
 
°
 
C for 5 min at the end
of the PCR. To discriminate the two major allelic types,
SSOP was subsequently performed as previously described,
with minor modifications (23,24). In brief, amplification
products were denatured and 1·5 
 
µ
 
L aliquots dotted onto
duplicate nylon membranes (BioBond
 
TM
 
 Plus, Sigma). The
membranes were then incubated with preheated (53
 
°
 
C) 3
 
′
 
digoxigenin-labelled probes (MSP3-3D7, 5
 
′
 
-GCAAAA-
GATGATGCTGA-3
 
′
 
 and MSP3-K1, 5
 
′
 
-GCAAAGAAA-
GCTGCTGA-3
 
′
 
) in TMAC hybridization solution for 90 min
at 53
 
°
 
C, with constant rotation in a hybridization oven,
followed by high stringency washes in TMAC. The probes
were detected using an alkaline phosphatase conjugated anti-
digoxigenin antibody Fab fragment (Boehringer, Mannheim,
Germany) and visualized using enhanced chemofluorescence
(ECF) substrate (Amersham Phamarcia Biotech). Membranes
were scanned on a Phosphorimager (STORM, Molecular
Dynamics) and scored independently by two investigators.
Most samples contained a single dominant allele (i.e. one
allele was clearly much stronger than the other). Each allele
was scored in samples that were strongly positive for both
alleles.
 
Statistical analysis
 
Data were analysed using 
 
 
 
version 9·2 (Statcorp, TX,
USA). The association between allele-specific antibody-
positivity (3D7 MSP3 and K1 MSP3) or antibody positivity
to the C-terminal of MSP3 in October 2000 and the propor-
tion of individuals developing malaria during the 6-month
follow-up period was investigated initially by univariate
analysis, and subsequently by multivariate analysis that
adjusted for age and reactivity to 
 
P. falciparum
 
 schizont
extract using generalized linear models (GLM) for the
binomial family that estimate the risk ratio (relative risk).
Previous studies have shown that the presence of parasitaemia
before the malaria transmission season (in October 2000)
significantly correlates with outcome (increased risk of
clinical malaria in the follow-up period) (21,22,25). Therefore
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the cohort was stratified into those who were slide positive
or slide negative at the time of serum collection in October
2000 and then analysed for associations between antibodies
and risk of subsequent disease in each stratum separately.
Associations between the major allelic types of MSP3 (
 
3D7-
like
 
 or 
 
K1-like
 
) in the infecting parasite, and the correspond-
ing allele-specific reactivity were tested in samples that
had a single dominant allele as previously described in a
study of  MSP2 (21). Antibody levels to 3D7 MSP3 were
compared between individuals that had a dominant 
 
3D7-
like
 
 allele and those with a dominant 
 
K1-like
 
 allele using
the Wilcoxon rank sum test. Likewise, antibody levels to
K1-MSP3 were compared between individuals that had a
dominant 
 
K1-like 
 
allele and those that had a dominant
 
3D7-like
 
 allele.
 
RESULTS
 
Heterogeneity of antibody reactivity to MSP3
 
There was a correlation between the reactivity of antibodies
to the MSP3 full-length antigens 3D7 MSP3 and K1 MSP3
in the indirect ELISA, pair wise correlation coefficient
0·6752, 
 
P
 
 = 0·0000, 
 
n
 
 = 536 (Figure 1). However, it is clear
from this scatter plot that many individuals only have strong
reactivity to one of the full-length antigens and not to the
other, while others have reactivity to both. In the competi-
tion ELISA using titred amounts of competing antigen in
selected sera (
 
n
 
 = 20), three different profiles of antibody
reactivity were noted. The first profile comprised of  sera
that had allele-specific reactivity to epitopes on only one
MSP3 antigen, and not the other (Figure 2; serum C166,
3D7-specific reactivity; serum C308, K1-specific reactivity).
The second profile was of  distinct mixed allele-specific
reactivity to both antigens of MSP3 (Figure 2; serum C137
and C427). The third profile was reflected in sera that had
both allele-specific, as well as conserved epitope reactivity
(Figure 2; serum C279 and C466). None of  the 20 sera
tested in this fashion contained reactivity only to conserved
epitopes.
 
Predominance of allele-specific reactivity over reactivity to 
conserved epitopes
 
One hundred and twenty-eight (24%) samples were sero-
negative for both the full-length MSP3 antigens. Samples
that were sero-positive for 3D7 MSP3 and not for K1 MSP3
in the indirect ELISA were considered to be allele-specific
for 3D7 MSP3 (
 
n
 
 = 109). Similarly, samples that were sero-
positive for K1 MSP3 and not for 3D7 MSP3 were considered
to be allele-specific for K1 MSP3 (
 
n
 
 = 43). For samples that
were sero-positive for both allelic antigens (
 
n
 
 = 258), the
presence of  allele-specific reactivity was determined by
competition ELISA (preincubation of test sera with 1000 ng
of  competing antigen). Of  these 258 samples, 132 (51%)
contained allele-specific antibodies to both 3D7 and K1
MSP3, while 29 (11%) contained antibodies to purely con-
served epitopes. The remaining 97 (38%) samples contained
antibodies to both allele-specific and conserved epitopes
(allele-specific for 3D7 MSP3 and conserved, 
 
n
 
 = 50; allele-
specific for K1 MSP3 and conserved, 
 
n
 
 = 47). As such,
the overall prevalence of allele-specific reactivity was 54%
(291/536) for 3D7 MSP3 and 41% (222/536) for K1 MSP3.
The prevalence of reactivity to C-terminal MSP3 was 24%
(126/531). The age specific prevalence of allele-specific reacti-
vity (K1 and 3D7 MSP3) and reactivity to the C-terminal is
shown in Figure 3. In the youngest children, allele-specific
reactivity to 3D7 MSP3 was much more common than
that of  K1 MSP3, but its prevalence rose during the first
10 years of life so that in older children the prevalence of
allele-specific reactivity was similar for both allelic antigens.
The prevalence of reactivity to C-terminal MSP3 appeared
to rise more slowly with age, being very low in children
< 10 years old.
 
IgG subclass reactivity to MSP3
 
Selected sera (
 
n
 
 = 96) that were sero-positive for antibodies
to both K1 and 3D7 MSP3 were investigated for IgG sub-
class reactivity. For both MSP3 antigens, a predominance of
Figure 1 Correlation between antibody reactivity to K1 MSP3 and 
3D7 MSP3 in the sera of 536 individuals from Chonyi village. 
Dashed lines indicate cut-off  values for positive reactivity for 
3D7 and K1 MSP3, respectively, as determined by mean + 3 SD of 
reactivity of 20 non-malaria exposed controls. Pair wise correlation 
coefficient was 0·6752, P = 0·0000, n = 536.
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IgG3 and IgG1 was found. A few subjects showed IgG4
reactivity, but virtually no reactivity was observed for IgG2
(Figure 4a,b).
Allelic typing of msp3
A total of 85 parasite positive samples taken in October
2000 were genotyped for 3D7-like and K1-like alleles of
MSP3. Sixty samples (71%) had one dominant allele, either
3D7-like (n = 52) or K1-like (n = 8). Twenty-five samples
(29%) were strongly positive for the two alleles and both
were counted. The total number of 3D7-like and K1-like
alleles counted was thus 77 and 33, with corresponding
population allele frequencies of 0·7 and 0·3, respectively.
The association between the infecting parasite genotype in a
blood sample and the corresponding allele-specific antibody
reactivity was analysed only in samples that contained one
dominant allele. There was no difference in antibody levels
(ELISA OD values) to 3D7 MSP3 in individuals that had
parasites bearing a dominant 3D7-like allele compared to
those bearing a dominant K1-like allele (Wilcoxon rank
sum test z = –0·783, P = 0·434). Similarly, no difference in
antibody levels to K1 MSP3 was observed in these two
groups (z = 0·957, P = 0·339).
Association between being positive for antibodies to 
MSP-3 alleles and protection from clinical malaria
The associations between being positive for antibodies to
MSP3 in October 2000 and the risk of developing clinical
malaria during the 6-month follow-up are presented in
Table 1. The presence of allele-specific antibodies to K1
MSP3 was associated with a lower risk of clinical malaria in
individuals who were parasitaemic in October 2000 before
the start of the malaria transmission season. This associa-
tion remained significant after adjusting for age and reactivity
to parasite schizont extract in multivariate analyses. It also
remained significant when antibody responses to AMA1
and MSP2 which have previously been shown to be associated
with protection in this cohort (21,22) were taken into account
(data not shown). Allele-specific antibodies to 3D7 MSP3
however, were not associated with a lower risk of malaria
episodes. In a separate analysis, antibody levels to either of
the full-length antigens (3D7 or K1 MSP3) were associated
Figure 2 Competition ELISA using titred amounts of competing antigen on six representative sera. Data on remaining 14 sera are shown in 
supplementary figures.
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with a lower risk of malaria episodes (data not shown).
Although antibodies to C-terminal MSP3 were associated
with a lower risk of  malaria in individuals who were
aparasitaemic in October 2000 in the univariate analysis,
this association was not significant when age and reactivity
to schizont extract were taken into account.
DISCUSSION
This study determined the prevalence of naturally acquired
IgG antibody reactivity to MSP3 and investigated whether
this correlated with protection from clinical episodes of
malaria in a rural Kenyan community. Overall, allele-specific
responses were more common than those to a recombinant
antigen representing a conserved portion of  MSP3 (54%
to 3D7 MSP3 and 41% to K1 MSP3 vs. 24% to C-terminal
MSP3). These results are similar to those of  a study in
The Gambia using similar recombinant MSP3 antigens
(18). Of note, the recombinant C-terminal MSP3 used in
this study does not include the sequence of  a synthetic
peptide (MSP3b) representing the conserved portion of the
MSP3 sequence that was found to mediate ADCI (13,16,17).
Antibodies to another merozoite surface protein MSP2
are also mainly directed against allele-specific rather than
conserved epitopes (26–32). As with most malaria antigens,
the prevalence of antibody to both the conserved and allele-
specific epitopes of MSP3 increased significantly with age.
In the subset of individuals tested, a mixed IgG3 and IgG1
reactivity was observed. A similar IgG subclass distribution
has been reported for reactivity to synthetic peptides rep-
resenting conserved parts of MSP3, and IgG3 to conserved
epitopes of  MSP3 (MSP3b) has been associated with
protection from malaria in field studies (13,17). Cytophilic
antibodies to MSP3 have been shown to inhibit parasite
growth in conjunction with monocytes both in vivo (11) and
in passive transfer experiments in immunodeficient mice in
vitro (12,13), in ADCI assays. Interestingly, vaccine induced
antibodies to MSP3 were predominantly of the IgG1 sub-
class in malaria naive volunteers, while naturally acquired
antibodies are mixed IgG3 and IgG1 (10). Nevertheless,
vaccine-induced IgG1 to MSP3 was still present and capable
of mediating ADCI of parasite growth in vitro 12 months
after vaccination (10).
The 3D7-like allele of msp3 was three times more common
in this population than the K1-like allele. This difference is
reflected in the age prevalence of allele-specific reactivity
with younger children acquiring antibodies to 3D7 MSP3
much earlier than those to K1 MSP3. Thus at population
level, the prevalence of allele-specific antibody reactivity to
MSP3 appears to reflect the prevailing allele-frequency of
the local parasite in children who are rapidly acquiring
natural immunity to malaria. At an individual level however,
there was no difference in antibody levels between individuals
who had either dominant allelic type of  MSP3. Positive
correlations between the infecting parasite genotype and the
specific antibody response at the individual level have been
Figure 3 Age-specific prevalence of anti-MSP3 antibodies. 
Numbers above each group of bars indicate the number of 
individuals in each age category. The presence of allele-specific 
reactivity to 3D7 and K1 MSP3 was determined as follows: samples 
that were sero-positive (serum IgG OD level above the mean + 3 SD 
of that of 20 non-malaria exposed sera) for 3D7 MSP3 and 
sero-negative for K1 MSP3 were considered to be allele-specific 
for 3D7-MSP3, and likewise for K1 MSP3; samples that were 
sero-positive for both 3D7 and K1 MSP3 were tested by 
competition ELISA and differences of > 0·3 OD units between the 
heterologous and homologous competition assays were counted as 
evidence of allele-specific reactivity. Samples were considered to be 
positive for C-terminal MSP3 if  the serum IgG OD level was above 
the mean + 3 SD of that of 20 non-malaria exposed sera.
Figure 4 (a, b) IgG subclass reactivity to 
MSP3 recombinant antigens, (a) 3D7 
MSP3 and (b) K1 MSP3, respectively. 
Horizontal bars indicate means (n = 96).
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observed for antibody responses to alleles of MSP1 block 2
in some (33,34) but not all studies (35,36).
Among individuals who were parasitaemic at the time
of  serum collection, allele-specific antibody responses to
K1 MSP3 were associated with a significantly lower risk of
malaria, even when the analyses were adjusted for age and
reactivity to P. falciparum schizont extract. Allele-specific
antibodies to 3D7 MSP3 and a C-terminal portion of MSP3
were not associated with a lower risk of malaria in this study.
For antibodies to C-terminal MSP3, this was not surprising,
given their low prevalence in this population. However, for
allele-specific epitopes it was unexpected that antibodies
targeted to the rarer allele would be associated with protec-
tion, while those directed against the commoner allele were
not. It is not clear why this should be the case. In The Gambia,
reactivity to both antigens was associated with a lower risk
of malaria (18). More studies in areas of differing endemic-
ity, and within different clinical categories of malaria will be
necessary to build a picture of the protective effect of natu-
rally acquired antibodies to MSP3. Nonetheless, this study
contributes to the evidence that allele-specific antibodies to
MSP3 are important in naturally acquired immunity to
malaria and may add value to an MSP3 malaria vaccine.
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Table 1 Antibodies to MSP3 in October 2000 and the risk of developing clinical episodes of malaria in the following 6 months
Antibody reactivity
Proportiona acquiring malaria 
among individuals who were: Univariate analysis Multivariate analysis
IgG positive IgG negative Risk ratio (95% CI) P-value Risk ratiob (95% CI) P-value
All individuals (n = 536)
Allele-specific K1 MSP3 8% (18/222) 20% (62/314) 0·41 (0·25–0·67) 0·000* 0·64 (0·38–1·08) 0·098
Allele-specific 3D7 MSP3 16% (46/291) 14% (34/245) 1·13 (0·75–1·71) 0·533 1·21 (0·81–1·79) 0·337
C-terminal MSP3c 8% (9/117) 17% (71/414) 0·44 (0·23–0·86) 0·018* 0·87 (0·44–1·69) 0·687
Slide positive individualsd (n = 196)
Allele-specific Kl MSP3 9% (9/101) 38% (36/95) 0·23 (0·11–0·46) 0·000* 0·41 (0·20–0·81) 0·011*
Allele-specific 3D7 MSP3 24% (28/119) 22% (17/77) 1·06 (0·62–1·81) 0·814 1·15 (0·83–1·60) 0·380
C-terminal MSP3c 16% (7/44) 25% (38/151) 0·63 (0·30–1·31) 0·220 1·37 (0·88–2·12) 0·158
Slide negative individualsd (n = 340)
Allele-specific K1 MSP3 7% (9/121) 12% (26/219) 0·62 (0·30–1·29) 0·206 1·14 (0·54–2·44) 0·717
Allele-specific 3D7 MSP3 10% (18/172) 10% (17/168) 1·03 (0·55–1·93) 0·916 1·07 (0·56–2·02) 0·824
C-terminal MSP3c 3% (2/73) 13% (33/263) 0·21 (0·05–0·88) 0·034* 0·39 (0·09–1·64) 0·202
Table shows the risk ratio (95% CI) of acquiring malaria among individuals who were positive for allele-specific antibodies to full-length MSP3 
recombinant antigens or antibody positive to recombinant C-terminal MSP3 in October 2000 compared to those who were antibody negative. 
aNumber of individuals acquiring malaria/total number of individuals that were serum IgG positive or IgG negative. bRisk ratio estimated 
from multivariate analyses adjusting for age and reactivity to P. falciparum schizont extract in generalized linear models. cFor reactivity to 
C-terminal MSP3 there were insufficient sera on five samples (slide all n = 531, slide positive n = 195, slide negative n = 336). dData stratified 
into two groups: individuals who were parasitaemic (or not) at the time of serum sampling in October 2000. *P < 0·05.
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